Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2026-02-06 Call Transcript
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 80% confidence The document is an intimation regarding the schedule of an Analysts/Investors Earnings Call for the quarter ended December 31, 2025. It references the financial results for Q3 FY 2025-26 but does not contain the financial results themselves. Instead, it announces the date and time of the earnings call where these results will be discussed. The document is short (3978 characters) and serves as a notice or invitation for the earnings call, not the transcript or the earnings release itself. Therefore, it is best classified as a Call Transcript (CT) related announcement or invitation. However, since it is only the schedule/intimation of the earnings call and not the transcript, the closest fitting category is Regulatory Filings (RNS) as a fallback for such announcements. But given the options and the document's nature, the best classification is Call Transcript (CT) with moderate confidence because it is about the earnings call event.
2026-02-06 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-02-06 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal notice addressed to stock exchanges regarding a scheduled Board Meeting to consider and approve unaudited limited reviewed financial results for the quarter ended December 31, 2025. It references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including board meetings. The document does not contain the financial results themselves but is an intimation or announcement of the upcoming board meeting where such results will be approved. The document length is short (2354 characters) and it serves as a prior intimation rather than the actual financial report. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a regulatory announcement about a board meeting and financial results approval, not the results or report itself.
2026-02-06 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for images and no substantive textual content or financial data. The true document length is only 285 characters, which is very short and does not contain any report or announcement details. There is no indication of any report type, regulatory body, or financial information. Given the lack of content, this document is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2026-01-08 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal notice from Orchid Pharma Limited regarding the closure of the trading window for insiders due to the upcoming declaration of unaudited limited reviewed financial results for the quarter ending December 31, 2025. It references regulatory compliance with SEBI regulations on insider trading and trading window closure periods. The document does not contain any financial statements, detailed financial data, or the actual financial results. It is a regulatory announcement about trading restrictions ahead of a financial report release. The document length is short (2709 characters) and it serves as an intimation or notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements that do not fit other specific categories.
2025-12-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call held by Orchid Pharma Limited on November 11, 2025, discussing the financial results for the second quarter of fiscal year 2026. It includes management commentary on financial performance, market conditions, strategic initiatives, and a Q&A session with analysts. The text explicitly mentions it is a transcript of an earnings call and contains detailed financial data and management discussion. Therefore, this document fits the definition of a Call Transcript (CT).
2025-11-17 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.